Exploring the Therapeutic Potential of N-Methyl-D-Aspartate Receptor Antagonists in Neuropathic Pain Management.
International journal of molecular sciences – October 16, 2024
Source: PubMed
Summary
Breakthrough medications like ketamine and memantine are showing promise in treating chronic nerve pain that doesn't respond to standard treatments. These NMDA receptor antagonists work by blocking specific brain receptors that amplify pain signals. Studies show that low doses of these medications, including methadone, can significantly reduce neuropathic pain and improve quality of life for patients.
Abstract
Neuropathic pain (NeP) is a complex and debilitating condition that impacts millions of people globally. Although various treatment options exist, their effectiveness is often limited, and they can be accompanied by significant side effects. In recent years, there has been increasing interest in targeting the N-methyl-D-aspartate receptor (NMDAR) as a potential therapeutic approach to alleviate different types of neuropathic pain. This narrative review aims to provide a comprehensive examination of NMDAR antagonists, specifically ketamine, memantine, methadone, amantadine, carbamazepine, valproic acid, phenytoin, dextromethorphan, riluzole, and levorphanol, in the management of NeP. By analyzing and summarizing current preclinical and clinical studies, this review seeks to evaluate the efficacy of these pharmacologic agents in providing adequate relief for NeP.